Leerink Partnrs Issues Negative Outlook for Bruker Earnings

Key Points

• Leerink Partners has revised down its Q4 2025 earnings estimate for Bruker Corporation to $0.90 per share, slightly lower than the previous estimate of $0.93.
• Bruker's recent earnings report showed a miss with $0.32 EPS against a consensus estimate of $0.33 and revenue of $797.40 million, falling short of the expected $811.17 million.
• Several brokerages, including UBS and Bank of America, have decreased their price targets for Bruker shares, signaling a cautious outlook on the stock amidst varying ratings from different analysts.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Analysts at Leerink Partnrs lowered their Q4 2025 earnings per share (EPS) estimates for Bruker in a research report issued to clients and investors on Monday, August 4th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.90 for the quarter, down from their previous forecast of $0.93. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q1 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.96 EPS, FY2026 earnings at $2.58 EPS and FY2027 earnings at $2.91 EPS.

Other equities research analysts have also issued reports about the stock. Barclays set a $43.00 price target on shares of Bruker and gave the company an "overweight" rating in a report on Monday. UBS Group decreased their price objective on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company lowered their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Tuesday. Stifel Nicolaus set a $40.00 price target on Bruker and gave the stock a "hold" rating in a research note on Tuesday. Finally, Citigroup reduced their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $51.30.

Bruker Stock Down 2.3%

Shares of BRKR traded down $0.73 during mid-day trading on Wednesday, reaching $30.43. 3,943,871 shares of the stock traded hands, compared to its average volume of 4,038,396. The stock has a fifty day simple moving average of $39.45 and a 200 day simple moving average of $42.65. Bruker has a 12-month low of $30.19 and a 12-month high of $72.94. The company has a quick ratio of 0.74, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 58.52, a P/E/G ratio of 2.58 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 earnings per share.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Insider Buying and Selling

In other news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was acquired at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the acquisition, the chief executive officer owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 27.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently added to or reduced their stakes in BRKR. Nisa Investment Advisors LLC raised its position in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after purchasing an additional 487 shares during the period. Pinnacle Bancorp Inc. bought a new position in Bruker during the 1st quarter worth $29,000. Allworth Financial LP grew its stake in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after buying an additional 364 shares during the last quarter. Huntington National Bank increased its position in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock worth $30,000 after buying an additional 645 shares during the period. Finally, Spire Wealth Management bought a new stake in Bruker in the second quarter valued at $32,000. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.